ArticleNucleic acids research2021
Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release.
Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Advances in DNA nanostructures for pathogenic microorganisms.Materials today. Bio · 2026Review
- Membrane-anchored DNA nanodevice with allosteric aptamer arms enables parallel probing and on-site drug delivery.Nature communications · 2026Article
- From single DNA molecule to nanoparticle formation: mechanistic basis for monocationic aromatic drug-induced DNA frameworks.Journal of nanobiotechnology · 2026Article
- Framework Nucleic Acids as a Nanocontainer for Delivering Heterogeneous Molecular Drugs.Pharmaceutics · 2026Review
- DNA as Drug Carrier: A Hydrophobic β-Cyclodextrin Channel in a Supramolecular Structure.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Biological Nanoscaffolds from Hierarchical Construction to Applications.Molecules (Basel, Switzerland) · 2026Review
- Bacteria-powered LA@CaDGP biomotor: a multi-modal weapon integrating calcium overload, chemotherapy, and starvation for breast cancer therapy.Journal of nanobiotechnology · 2026Article
- Plain DNA and cationic aromatics: a platform to simplify carrier-free delivery systems.Journal of nanobiotechnology · 2025Article
- Mechanism-informed identification of FDA-approved topoisomerase inhibitors disrupting SARS-CoV-2 nucleocapsid-RNA interactions.BMC chemistry · 2025Article
- Nucleic Acid Nanoparticles Redefine Traditional Regulatory Terminology: The Blurred Line between Active Pharmaceutical Ingredients and Excipients.ACS nano medicine · 2025Article
- Aptamers as target-specific recognition elements in drug delivery.Advanced drug delivery reviews · 2025Review
- Design and Assembly of a Cargo-Agnostic Hollow Two-Lidded DNA Origami Box.ACS applied bio materials · 2025Article
- Fluorescence Anisotropy for Detailed Analysis of Doxorubicin Loading into DNA Origami Nanocarriers for Drug Delivery.ACS applied nano materials · 2025Article
- Interaction of Selected Anthracycline and Tetracycline Chemotherapeutics with Poly(I:C) Molecules.ACS omega · 2025Article
- Review
- Doxorubicin-loaded DNA origami nanostructures: stability in vitreous and their uptake and toxicity in ocular cells.Nanoscale · 2024Article
- The unusual structural properties and potential biological relevance of switchback DNA.Nature communications · 2024Article
- Predicting the effect of binding molecules on the shape and mechanical properties of structured DNA assemblies.Nature communications · 2024Article
- Development of Bivalent Aptamer-DNA Carrier-Doxorubicin Conjugates for Targeted Killing of Esophageal Squamous Cell Carcinoma Cells.International journal of molecular sciences · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a common drug in cancer chemotherapy, and its high DNA-binding affinity can be harnessed in preparing DOX-loaded DNA nanostructures for targeted delivery and therapeutics. Although DOX has been widely studied, the existing literature of DOX-loaded DNA-carriers remains limited and incoherent. Here, based on an in-depth spectroscopic analysis, we characterize and optimize the DOX loading into different 2D and 3D scaffolded DNA origami nanostructures (DONs). In our experimental conditions, all DONs show similar DOX binding capacities (one DOX molecule per two to three base pairs), and the binding equilibrium is reached within seconds, remarkably faster than previously acknowledged. To characterize drug release profiles, DON degradation and DOX release from the complexes upon DNase I digestion was studied. For the employed DONs, the relative doses (DOX molecules released per unit time) may vary by two orders of magnitude depending on the DON superstructure. In addition, we identify DOX aggregation mechanisms and spectral changes linked to pH, magnesium, and DOX concentration. These features have been largely ignored in experimenting with DNA nanostructures, but are probably the major sources of the incoherence of the experimental results so far. Therefore, we believe this work can act as a guide to tailoring the release profiles and developing better drug delivery systems based on DNA-carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.